Similar articles

• Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes.

  Neuen BL, Solomon SD. Neuen BL, et al. J Am Coll Cardiol. 2024 Aug 20;84(8):709-711. doi: 10.1016/j.jacc.2024.07.002. J Am Coll Cardiol. 2024. PMID: 39142724 No abstract available.
• SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?

  Mone P, Ciccarelli M, Jankauskas SS, Guerra G, Vecchione C, Visco V, Santulli G. Mone P, et al. Lancet Healthy Longev. 2024 Sep;5(9):100632. doi: 10.1016/j.lanhl.2024.08.001. Epub 2024 Sep 13. Lancet Healthy Longev. 2024. PMID: 39284335 Free PMC article. No abstract available.
• Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?

  Packer M. Packer M. Am J Med. 2018 May;131(5):461-463. doi: 10.1016/j.amjmed.2017.11.052. Epub 2018 Jan 5. Am J Med. 2018. PMID: 29309741 No abstract available.
• How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.

  Lee MMY, Petrie MC, McMurray JJV, Sattar N. Lee MMY, et al. Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30. Arterioscler Thromb Vasc Biol. 2020. PMID: 31996025 Review.
• Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.

  Lajara R. Lajara R. Postgrad Med. 2019 Nov;131(8):555-565. doi: 10.1080/00325481.2019.1670017. Epub 2019 Oct 3. Postgrad Med. 2019. PMID: 31580737 Review.